Matthew K. Fust - Jun 18, 2024 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role
Director
Signature
/s/ Karah Parschauer, attorney-in-fact
Stock symbol
RARE
Transactions as of
Jun 18, 2024
Transactions value $
$0
Form type
4
Date filed
6/20/2024, 02:26 PM
Previous filing
Jun 14, 2024
Next filing
Oct 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Award $0 +5.35K +35.97% $0.00 20.2K Jun 18, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RARE Stock Option (Right to Buy) Award $0 +9.9K $0.00 9.9K Jun 18, 2024 Common Stock 9.9K $37.42 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 18, 2025.
F2 The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 18, 2025.